Unlocking the Potential of Medical Imaging as Real-World Data

In the drug development process, where RWD is playing an increasingly important role, medical imaging is not often among the data that teams are actively leveraging. But information acquired via different imaging modalities can be used to better characterize disease mechanisms and provide insights to therapeutic responses. This information could directly impact the speed of delivery, as well as precision for much-needed therapeutics. For example, larger and more realistic data sets may lead to more accurate predictive models to inform clinical trial protocols that select more targeted patient cohorts and help identify novel biomarkers as objective study endpoints. 

Read this article in American Pharmaceutical Review to learn how pharmaceutical companies are now more frequently requesting to take back possession of imaging datasets from CROs and other partners and standardizing and organizing their imaging studies for complex analysis and machine learning.